Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	122724
DOI	10.4251/wjgo.122724
Country	China

Category	Oncology
Manuscript Type	Retrospective Study
Article Title	Prognostic value of the prognostic immune-inflammatory-nutritional score in patients with advanced gastric cancer treated with immunochemotherapy
Manuscript Source	Unsolicited Manuscript
All Author List	Qiu-Lin Hao, Zheng-Yu Li, Zhi-Yuan Yao, Yu-Meng Shen, Dong-Shan Sun, Chao Gao and Ran-Ran Jiang
Funding Agency and Grant Number	Funding Agency Grant Number the Advanced Program of The Affiliated Hospital of Xuzhou Medical University No. PYJH2025312 The Affiliated Hospital of Xuzhou Medical University No. 2023ZL07
Corresponding Author	Ran-Ran Jiang, MD, PhD, Professor, Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, No. 99 Huaihai Road, Xuzhou 221002, Jiangsu Province, China. xyfyjrr@126.com
Key Words	Gastric cancer; Prognostic immune-inflammatory-nutritional score; Programmed death-1 inhibitor; Predictive model; Immunochemotherapy
Core Tip	Advanced gastric cancer shows poor prognosis and heterogeneous response to first-line immunochemotherapy. The prognostic immune-inflammatory-nutritional (PIIN) score, combining neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, fibrinogen, albumin-bilirubin, and prognostic nutritional index, independently predicts survival in advanced gastric cancer patients treated with sintilimab plus chemotherapy. Lower PIIN scores correlate with longer progression-free survival, overall survival, and higher disease control. Nomograms integrating PIIN, TNM stage, programmed death-ligand 1, mismatch repair status, and Eastern Cooperative Oncology Group performance status provide individualized prognostic assessment to guide treatment.
Citation	Hao QL, Li ZY, Yao ZY, Shen YM, Sun DS, Gao C, Jiang RR. Prognostic value of the prognostic immune-inflammatory-nutritional score in patients with advanced gastric cancer treated with immunochemotherapy. World J Gastrointest Oncol 2026; In press DOI: https://doi.org/10.4251/wjgo.122724
PDF	122724-in-press.pdf

Received	2026-04-27 06:30
Peer-Review Started	2026-04-27 06:31
First Decision by Editorial Office Director	2026-05-15 09:28
Return for Revision	2026-05-15 09:28
Revised	2026-05-27 08:11
Publication Fee Transferred	2026-06-01 14:16
Second Decision by Editor	2026-06-29 02:20
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-06-29 05:33
Articles in Press	2026-06-29 05:33
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1948-5204 (online)
Open Access	This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright	©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com